Prostatic Artery Embolization for Benign Prostatic Obstruction
Primary Purpose
Hyperplasia Prostatic, Lower Urinary Tract Symptoms, Prostatic Diseases
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Prostatic Artery Embolization
Sponsored by
About this trial
This is an interventional treatment trial for Hyperplasia Prostatic focused on measuring Benign prostatic obstruction, benign prostatic enlargement, benign prostatic hyperplasia, prostatic artery embolization, Quality of Life, IPSS, DAN-PSS, Complications
Eligibility Criteria
Inclusion Criteria:
- Indwelling catheter secondary to benign prostatic hyperplasia (BPH) or
- Moderate-severe Obstructive LUTS secondary to BPH refractory to medical treatment
- Unsuitable for TURP or refuse surgery
Exclusion Criteria:
- Bladder dysfunction(and known neurological conditions affecting bladder function)
- Urethral strictures
- Bladder neck contracture
- Known sphincter anomalies
- Big bladder diverticulum or stones
- Kidney insufficiency (eGFR < 45)
- Coagulation disturbances
- Severe atheromatous or tortuosity of arteries
- Allergy to contrast medium
- Unable to undergo MR imaging
- Urological malignancy
Sites / Locations
- Rigshospitalet
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Prostatic Artery Embolization
Arm Description
Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
Outcomes
Primary Outcome Measures
Ability to void spontaneously
Patient demonstrate the ability to void spontanously after the removal of the indwelling catheter at 6 months
Secondary Outcome Measures
IPSS
International Prostate Symptom Score from 0-35, 35 is most severe symptoms
QoL
Quality of Life scored from 0-6, 6 is worst
IIEF
International Index of Erectile Function scored from 0-25, where higher scores represents better erectile function
PV
Prostate Volume measured by MRI
PVR
Post-void residual
Qmax
Peak void flow
PSA
Prostate-specific antigen
Full Information
NCT ID
NCT03099421
First Posted
March 28, 2017
Last Updated
December 18, 2018
Sponsor
Rigshospitalet, Denmark
1. Study Identification
Unique Protocol Identification Number
NCT03099421
Brief Title
Prostatic Artery Embolization for Benign Prostatic Obstruction
Official Title
Prostatic Artery Embolization for Benign Prostatic Obstruction
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
March 22, 2017 (Actual)
Primary Completion Date
December 14, 2018 (Actual)
Study Completion Date
December 14, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to investigate the safety and efficacy of prostatic artery embolization (PAE) for patients who refuse or are not eligible for surgery with moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign prostate obstruction due to benign prostatic hyperplasia.
Detailed Description
This is a prospective study investigating the safety and efficacy of PAE for patients who refuse or are not eligible for surgery and who suffers from moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign prostatic obstruction due to benign prostatic hyperplasia. It may form the grounding for further research in the shape of a larger randomised clinical trial.
Our hypothesis is that PAE will eliminate the need for indwelling catheter and improve IPSS 6 months post-procedure.
1, and 6 months follow-up.
Main outcome Ability to void after removal of indwelling catheter
Secondary outcomes International Prostate Symptom Score (IPSS) Quality of Life (QoL) International Index of Erectile Function (IIEF) Prostate volume Peak void flow (Qmax) Post-void residual (PVR) Classify complications according to Society of Interventional Radiology (SIR) guidelines for reporting Prostate-specific antigen (PSA)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperplasia Prostatic, Lower Urinary Tract Symptoms, Prostatic Diseases, Urological Manifestations
Keywords
Benign prostatic obstruction, benign prostatic enlargement, benign prostatic hyperplasia, prostatic artery embolization, Quality of Life, IPSS, DAN-PSS, Complications
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Prostatic Artery Embolization
Arm Type
Experimental
Arm Description
Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
Intervention Type
Procedure
Intervention Name(s)
Prostatic Artery Embolization
Intervention Description
The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
Primary Outcome Measure Information:
Title
Ability to void spontaneously
Description
Patient demonstrate the ability to void spontanously after the removal of the indwelling catheter at 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
IPSS
Description
International Prostate Symptom Score from 0-35, 35 is most severe symptoms
Time Frame
1, 6 months
Title
QoL
Description
Quality of Life scored from 0-6, 6 is worst
Time Frame
1, 6 months
Title
IIEF
Description
International Index of Erectile Function scored from 0-25, where higher scores represents better erectile function
Time Frame
1, 6 months
Title
PV
Description
Prostate Volume measured by MRI
Time Frame
1, 6 months
Title
PVR
Description
Post-void residual
Time Frame
1, 6 months
Title
Qmax
Description
Peak void flow
Time Frame
1, 6 months
Title
PSA
Description
Prostate-specific antigen
Time Frame
1, 6 months
10. Eligibility
Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Indwelling catheter secondary to benign prostatic hyperplasia (BPH) or
Moderate-severe Obstructive LUTS secondary to BPH refractory to medical treatment
Unsuitable for TURP or refuse surgery
Exclusion Criteria:
Bladder dysfunction(and known neurological conditions affecting bladder function)
Urethral strictures
Bladder neck contracture
Known sphincter anomalies
Big bladder diverticulum or stones
Kidney insufficiency (eGFR < 45)
Coagulation disturbances
Severe atheromatous or tortuosity of arteries
Allergy to contrast medium
Unable to undergo MR imaging
Urological malignancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lars Lönn, Professor
Organizational Affiliation
Radiologisk Klinik, Rigshospitalet
Official's Role
Study Chair
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Prostatic Artery Embolization for Benign Prostatic Obstruction
We'll reach out to this number within 24 hrs